NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Nexaph

Published 12 Nov 2026. 39-page investigative report on who is behind Nexaph: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 308 Finnrick lab tests, Nexaph's overall pass rate is 61% (189 pass / 118 fail). The useful read is product-specific, and ratings contract under stricter grading where fill or quantity drives outcomes: GHK-Cu and Tirzepatide create the strongest buyer case, while Semaglutide and Tesamorelin sit on the weak side. The full report separates current routine-test strength from a documented older Tirzepatide T30 sterility-failure thread rather than letting either fact erase the other.

Nexaph looks operationally mature: login-gated kit sales, Telegram/community surfaces, a wholesale portal, domestic-fulfillment signals, and a materially improved COA portal. The accountability layer is less settled. A Shanghai Nexa Pharma Co label, Nevis governing-law clause, Indiana operating signals, and China-origin synthesis evidence with possible U.S. finishing do not yet resolve the legal counterparty, UBO, facility, or batch-release authority.

The certificate story is mixed in a buyer-relevant way. Active and previous Janoshik records, task keys, and sterility/endotoxin/heavy-metal tabs improve traceability, but the proof remains batch-level, not vial-level; one pre-order example still showed pending results after the stated ship date. Identical reports appearing across Nexaph and related-brand channels further reduce the strength of any brand-name COA standing alone.

Payment and recourse deserve equal attention. Nexaph promotes a crypto discount through a hosted BTCPay route while using all-sales-final language and publishing no clear failed-batch refund, recall, or quarantine process. For a buyer, Nexaph is not a single yes/no call: it is a current-batch, product-specific decision with extra diligence around certificates, payment method, and remedy terms.

Inside the full report:

  • Per-product pass/fail rates, methodology-divergence charts, and Appendix A lab data for all 16 products
  • Tirzepatide T30 sterility-event exhibit and current-batch comparison
  • COA portal walkthrough with Janoshik task/key checks, pre-order timing, and cross-brand reissuance evidence
  • Ownership, legal-counterparty, and manufacturing-origin analysis using policy pages, domain/DNS records, and registry checks
  • Sister-brand and channel-authenticity map covering EZ Peptides, IRON Peptides, Nexa Labs, Telegram, and wholesale endpoints
  • Payment, final-sale, Lab Seconds, and missing-remedy analysis

Risk assessment

  • Product-specific quality risk — Tesamorelin, Semaglutide, MOTS-c, CJC-1295, TB-500, Sermorelin, NAD+ — high: Nexaph is weak for these specific products in Finnrick's record: NAD+ 24.96%, MOTS-c 29.37%, Semaglutide 34.64%, CJC-1295 34.99%, Sermorelin 36.41%, TB-500 36.91%, and Tesamorelin 37.2%.
  • Tirzepatide T30 sterility-control risk — high: Public GLP-1 Forum reporting says 3 of 4 tested batches of 2TZ3012242025-20 failed sterility; S. pasteuri was reported and no public Nexaph recall was located.
  • Corporate-accountability / UBO opacity — high: Site uses Shanghai Nexa Pharma Co without jurisdiction, registration, office, officers, members, shareholders, or parent; Terms select Nevis law; Cain R. McQuinley is best-supported operator but UBO remains unresolved.
  • Manufacturing-origin / sterile-facility transparency concern — high: China-origin synthesis is better supported than full U.S. manufacture; no Nexaph facility, clean-room certificate, ISO/FDA record, environmental-monitoring record, or independent audit was found.
  • COA / batch-traceability risk — medium: The COA portal improves retrieval and verification, but evidence remains batch-level, not vial-level; cross-brand Janoshik reissuance and pre-order-before-COA practice weaken traceability.
  • Buyer-recourse / final-sale / pre-order risk — medium: Terms say all sales final; no public failed-batch, recall, or lost-parcel procedure was located; pre-orders can ship before a public COA exists.
  • Crypto payment irreversibility / merchant-of-record risk — medium: Nexaph promotes a 5% crypto discount through a hosted BTCPay surface; crypto removes chargeback leverage while the legal counterparty remains unresolved.
  • Copycat / brand-confusion risk — medium: Nexa/Nexaph lookalike domains, Nexa Labs, fake-group warnings, and parasite-SEO pages exist; Nexaph publishes no authorized-reseller list, vial-level anti-counterfeit program, or signed authenticity channel.
  • Lab Seconds final-sale defect risk — medium: Applies to Lab Seconds SKUs such as ARA-290: Nexaph discloses cracked/collapsed cake and below-standard lot possibility, but sells the category as-is with no returns, exchanges, or reships for cosmetic condition.